Archives

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

Learn More

Harnessing the Power of CytomX’s Probody® Technology to Drug the Undruggable

Alison L. Hannah, MD. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Utilizing Probody® Technology to Develop Therapeutics to Undruggable Targets

Bob Liu, Ph.D. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Autio KA, Boni V, Humphrey RW, Naing A. Clin Cancer Res. 2020 26(5): 984-989. doi:10.1158/1078-0432.CCR-19-1457.

Learn More

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Giesen D, Broer LN, Lub-de Hooge MN, et al. Clin Cancer Res. January 17, 2020; doi: 10.1158/1078-0432.CCR-19-3137.

Learn More

The Tumor Targeting Performance of Anti-CD166 Probody Drug Conjugate CX-2009 and its Parental Derivatives as Monitored by 89Zr-immuno-PET in Xenograft Bearing Mice

Chomet M, Schreurs M, Nguyen M, et al. Theranostics. 2020; 10(13): 5815-5828. doi:10.7150/thno.44334.

Learn More

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab

Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Albert Louis Maria Eskens, Rachel E. Sanborn, Nataliya Uboha, Daniel Cho, Alexander I. Spira, Igor Bondarenko, Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, E.G.E. DeVries, Will Garner, Hendrik-Tobias Arkenau, Johanna Bendell. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Evidence of Intratumoral Localization, Activation, and Immunomodulatory Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Aung Naing, Ivan A. Zein, Yuanbin Ru, Bruce Howng, Michael B. Winter, Olga Vasiljeva, Will Garner, Beiyao Zheng, Mark Stroh, Hong Lu, Jennifer Richardson, W. Michael Kavanaugh, Luc R. Desnoyers. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166

Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More